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Abstract
Background: Type 2 diabetes (T2D) brings significant human and healthcare costs. Its progressive nature means
achieving normoglycaemia is increasingly difficult, yet critical to avoiding long term vascular complications. Nearly
one-half of people with T2D have glycaemic levels out of target. Insulin is effective in achieving glycaemic targets,
yet initiation of insulin is often delayed, particularly in primary care. Given limited access to specialist resources and
the size of the diabetes epidemic, primary care is where insulin initiation must become part of routine practice. This
would also support integrated holistic care for people with diabetes. Our Stepping Up Program is based on a
general practitioner (GP) and practice nurse (PN) model of care supported appropriately by endocrinologists and
credentialed diabetes educator-registered nurses. Pilot work suggests the model facilitates integration of the
technical work of insulin initiation within ongoing generalist care.
Methods: This protocol is for a cluster randomized controlled trial to examine the effectiveness of the Stepping Up
Program to enhance the role of the GP-PN team in initiating insulin and improving glycaemic outcomes for people
with T2D. 224 patients between the ages of 18 and 80 years with T2D, on two or more oral hypoglycaemic agents
and with an HbA1c ≥7.5% in the last six months will be recruited from 74 general practices. The unit of
randomization is the practice.
Primary outcome is change in glycated haemoglobin HbA1c (measured as a continuous variable). We hypothesize
that the intervention arm will achieve an absolute HbA1c mean difference of 0.5% lower than control group at 12
months follow up. Secondary outcomes include the number of participants who successfully transfer to insulin and
the proportion who achieve HbA1c measurement of <7.0%. We will also collect data on patient psychosocial
outcomes and healthcare utilization and costs.
Discussion: The study is a pragmatic translational study with important potential implications for people with T2D,
healthcare professionals and funders of healthcare though making better use of scarce healthcare resources,
improving timely access to therapy that can improve disease outcomes.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12612001028897
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Background
Type 2 diabetes (T2D) is a costly, epidemic condition [1,2].
In Australia, T2D is anticipated to be the leading cause of
disease burden by 2016 [2], costing over $14 billion annu-
ally in direct and indirect healthcare costs [3], and shorten-
ing life expectancy by up to five years. We can expect an
exponential rise in the human and healthcare costs associ-
ated with T2D [4].
Because T2D is a progressive condition, involving
beta cell failure in the presence of insulin resistance,
normoglycaemia is increasingly difficult to achieve [5].
Hyperglycaemia causes microvascular and macrovas-
cular complications through glycation and oxidation
of proteins [6]. Conversely, achieving optimal glycaemic
control early in the course of the disease reduces the risk
of vascular complications as well as mortality [7]. The
most recent Australian Diabetes Society (ADS) guidelines
[8] recommend individualized glycaemic targets (HbA1c)
based upon diabetes duration, age, and co-morbidity, yet
in Australia, only 52% of people with T2D achieve an
HbA1c below 7% (53 mmol/mol).
Early use of insulin as a part of treatment intensifica-
tion for people with T2D is supported by both American
and European guidelines [9-11]. The effectiveness of in-
sulin in improving glycaemic control in T2D has been
shown in clinical trials, largely in secondary care [12-15].
The use of long-acting insulin analogues with simple
patient-driven algorithms is feasible, safe (low incidence
of hypoglycaemia), effective in achieving glycaemic con-
trol [13,14], and associated with improved patient satis-
faction [16].
Despite evidence of the effectiveness of insulin and
endorsement of its early use in guidelines, in practice,
initiation of insulin is often delayed. The mean HbA1c
of people with T2D prior to starting insulin is 9.4%
(79.2 mmol/mol) in Australia (after a median diabetes
duration of 8.1 years) [17], and 9.3% (78.1mmol/mol) in
the UK [18], well above recommended targets. This has
been attributed, in part, to ‘psychological insulin resist-
ance’ (negative perceptions and attitudes that act as
barriers to starting insulin) [19] among people with T2D
and ‘clinical inertia’ (recognition of a problem but failure to
act) among practitioners [20]. However, health system
factors also play a role. While the majority of care for
people withT2D takes place in general practice, insulin ini-
tiation is commonly deferred to specialist diabetes service
[21,22], and the majority of Australians with T2D initiate
insulin within specialist settings [23]. Difficulties accessing
endocrinologists and diabetes nurse educators because of
cost and limited availability can lead to delays in starting
insulin, and avoidable periods of hyperglycaemia.
While specialist diabetes services have a role in man-
aging complex cases, initiating insulin in routine general
practice has several benefits. For example, diabetes care
can remain integrated with care for other conditions, as
glycaemic control is often just one facet of managing mul-
tiple co-morbidities. Furthermore, as secondary care is
costly [24], there are considerable economic benefits to
retaining T2D care in general practice. However, achieving
timely and effective insulin initiation as a routine aspect of
care in general practice presents some challenges. GPs are
more reluctant than specialists to start insulin [25], and
up-titrating to achieve glycaemic targets is also a chal-
lenge. A Canadian trial utilising community pharmacists
and specialist nurses to support general practice-based in-
sulin initiation did not show any improvement in insulin
prescribing rates or in glycaemia [26]. An intensive educa-
tional intervention for GPs and PNs in the UK has been
evaluated using clinical audit data from 115 practices; it
showed significantly improved glycaemic control at six
months in patients who started insulin, although further
improvement was not observed over 36 months [27]. In
Australia, 63% of general practices employ close to eleven
thousand PNs across the country [28]. They are a rapidly
growing sector of the primary care workforce and now
core members of the general practice team supported by
significant government investment.
We have designed and piloted for feasibility [29] an
education and system-change intervention (the Stepping
Up Program—described in more detail below) to facili-
tate general practice-based insulin initiation in people
with T2D and suboptimal glycaemic outcomes who are
on maximum oral therapy. The program is based on a
model of care that focuses on the ‘in-practice team’ (GP
and PN), supported appropriately by endocrinologists and
credentialed diabetes educator-registered nurses (CDE-
RNs). Our model acknowledges the importance of endo-
crinologists and CDE-RNs in providing support to GP/PN
teams in initiating insulin when needed. Our pilot work
[29] highlighted how this model of care supported integra-
tion of the technical work of insulin initiation within on-
going generalist care. Issues of clinical accountability and
flexibility, managing time and resources were highlighted
as important.
In this paper, we describe the protocol for a cluster ran-
domized controlled trial to examine the effectiveness of
the Stepping Up Program to enhance the role of the GP-
PN team in initiating insulin and improving glycaemic
outcomes for people with T2D. Our primary outcome is
change in HbA1c (measured as a continuous variable).
We hypothesize that participants in the intervention arm
will achieve an absolute HbA1c mean difference of 0.5%
lower than control group participants at 12 months follow
up. Secondary outcomes are described below.
Methods
This study is a cluster randomized controlled trial, con-
ducted in 74 general practices across the Australian state
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of Victoria. The consort diagram is provided in Additional
file 1. Ethical approval was received from the University of
Melbourne Health Sciences Human Research Ethics
Sub-committee (ID 123740). The trial is registered with
the Australian and New Zealand Clinical Trials Registry
(ACTRN12612001028897).
Recruitment and randomization of practices
Eligible general practices must have a current PN. Prac-
tices are recruited using our University Department of
General Practice database (the VicREN practice based
Research Network) and through Medicare Locals. Prac-
tice randomization is stratified by practice size, location
in Community Health Centers, and participation in the
National Primary Care Collaboratives.
The unit of randomization is the practice. Practices are
randomized after consenting, and following recruitment
of at least one eligible patient (Additional file 1). Due to
the nature of the intervention and because further patient
recruitment often occurs over a period of months subse-
quent to randomization, full allocation concealment is not
possible. Randomization is in blocks, undertaken by a
statistician at the University of Melbourne independent
of the research team. Following randomization, the re-
search team assist practices to continue to identify and
recruit patients.
Participant eligibility
Eligible patients are those with most recent HbA1c (in the
previous six months) ≥7.5% and who are on maximal oral
therapy but not currently on insulin. Maximal oral therapy
is defined as using at least two oral hypoglycaemic agents
(OHAs) (metformin, sulphonylurea, TZDs, DPP-4 inhibi-
tor) at maximal tolerated doses. Congruent with the prag-
matic, translational nature of this trial, patients are also
eligible if their responsible medical practitioner is of the
opinion that insulin is appropriate despite the patient
being on less than two OHAs or not at maximal dose. Pa-
tients are ineligible if they are >80 years old, have unstable
cardiovascular disease, are unable to give informed con-
sent or have a complex debilitating medical condition, e.g.,
severe mental illness, end-stage cancer.
Participant identification and recruitment
Patient identification is conducted by practices employ-
ing a number of methods to generate a comprehensive
list of potentially eligible patients. Search methods vary
by practice but include searching the practice electronic
medical records database, using the Pen clinical audit
tool [30], or obtaining a list of HbA1c results from the
local pathology providers. Our previous research and pilot
suggests an average general practice (of two full-time GPs)
has 80 to 100 identified patients with T2D, 10% to 15%
(8 to 15) of whom meet inclusion criteria.
Recruitment involves a letter from the practice inviting
eligible patients to participate and a follow-up call from
the PN and/or GP. The invitation letter states that par-
ticipants may benefit from assessment and more inten-
sive treatment of their diabetes and that insulin may be
a part of that program. Patients are invited to express
interest in receiving further details about the study, to
attend the practice to learn more about the study from a
member of the study team. If the patient agrees to par-
ticipate, consent and baseline data are collected at that
visit. Patients are asked to have their HbA1c checked
and are subsequently excluded if the result is <7.5%.
Study intervention
Our intervention is targeted at the decision to initiate
insulin and the care processes involved in implementing
that decision. The Stepping Up Program intervention
(Additional file 2) is designed to address barriers we
have identified. GPs and PNs in intervention practices
participate in the Stepping Up Program elements: in-
practice briefing and training visit, and ongoing support
for practice and PN in working with patients.
The aim of the training is to ensure GP/PN teams have
the knowledge and confidence to initiate a discussion with
eligible patients about commencing insulin, knowing that
they will be able to act on this within current routine
clinical care using a simple, safe, convenient evidence-
based algorithm. Referral or consultation with an Endo-
crinologist, CDE-RN or any other appropriate health
professional will naturally be management options for
GPs managing study patients. GPs and PNs are provided
with patient packs for each of the participating patients
whom they review.
In control group practices, GPs are sent a copy of Royal
Australian College of General Practitioners (RACGP)
guidelines for the management of T2D and a list of par-
ticipating patients and asked to undertake a clinical review
of those patients. Control group practices will be offered
the Stepping Up training after the 12-month follow up.
Following recruitment and baseline data collection,
participants are invited to attend their GP for an assess-
ment to discuss their diabetes. For the first participant
this is at a time when the Study CDE-RN is available to
support the PN. Participants in intervention practices are
managed according to the Stepping Up Program by GP
and PN who have attended the Stepping Up Training.
When participants attend, the GP reviews their diabetes
and if appropriate makes a clear recommendation for the
need to commence insulin, refers the participant to the
PN and writes a prescription for Glargine Insulin. The
participant sees the PN (supported by the Study CDE-RN)
on that day for an insulin initiation assessment, during
which time the PN and the Study CDE-RN work through
the patient pack with the participant. At that visit the PN,
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supported by the CDE-RN, gives the first dose of Glargine
insulin 10 units. The PN has the option to review the par-
ticipant on day two, and observe the participant give their
second dose of Glargine 10 units to themselves if they are
not already comfortable to do this at home. Subsequently
participants are asked to call the PN for review by phone
every three days. The participant records fasting morning
blood glucose in the record book provided and is encour-
aged to discuss the results with the PN and follow the
simple protocol (see Additional file 3). After four weeks, if
fasting blood glucose levels (FBGLs) are at target (<7), par-
ticipants are reviewed by the GP and a three-day blood
glucose level (BGL) profile is completed to identify the
meal with the largest postprandial (PP) excursion. Apidra
is then commenced at this meal and again adjusted to a
simple protocol based on an average PPBGL over three
days related to that mealtime (see Additional file 3). GPs
review participating participants at least every four weeks.
The GPs initiate and prescribe insulin, while the insulin
adjustment is led primarily by PN and participant in
discussion and in liaison with the GP as necessary.
All participants, even if not commencing insulin at the
first GP/PN visit, continue to see the PN and GP with
the aim of commencing insulin. GPs and PNs see partic-
ipants on as many occasions as is clinically necessary
over a period of up to 12 months drawing as needed on
the Stepping Up Program manual and resources.
Participants in control practices are managed by their
GP according to usual care (e.g., referral, investigation,
and adjustment of medication as the GP believes clinic-
ally appropriate).
Specific role of the practice nurse
PNs lead and drive the dialogue with participants around
the issue of intensifying treatment through insulin initi-
ation. PNs do not prescribe or manage dosing of insulin
without liaison with the GP. Our training directly ad-
dresses any GP or PN reluctance to initiate insulin, as well
as developing in-practice systems to support the initiation
process. This process is well within the legal scope of prac-
tice for PNs. Any clinical concerns beyond the conservative
simple clinical protocol can be addressed through consult-
ation with an endocrinologist or local CDE-RN in the usual
manner. Ongoing care of complex and co-morbid condi-
tions continues as per usual care.
Data collection and outcomes measures
Outcomes
The primary outcome is change in HbA1c (measured as a
continuous variable). Secondary outcome measures in-
clude the number of participants who successfully transfer
to insulin and the proportion of participants who achieve
HbA1c measurement of <7.0%. We will also collect data
on other outcome measures of interest including the
proportion of participants who achieve individualized
HbA1c targets according to Australian Diabetes Society
guidelines, changes in psychometric scores including
AQoL-8D, PHQ-9 and PAID and net healthcare utilization
and costs. Research assistant (RA) staff will collect partici-
pant data at baseline and at 12 months using the instru-
ments and measures outlined in Table 1. HbA1c is also
collected at six months.
All participants (intervention and control) are provided
with a BGL meter (Performa Nano™; Roche Diagnostics)
and are instructed how to use the meter. Data from BGL
meter are uploaded at each practice visit and at 12 months
by PNs to a secure server.
A pre-printed pathology form (HbA1c) with partici-
pant and practice details entered is mailed out to study
participants by the study RA five months after the base-
line visit with the GP at which anthropometric data was
collected. HbA1c results five to seven months from the
baseline date will be accepted as the mid-study HbA1c.
Additional data will be collected to inform the
economic evaluation: resources used to administer the
intervention; subsequent changes in participant’s health
service utilization during the 12-month follow-up period;
and use and cost of medical services (data gathered by
accessing health service and pharmaceutical data from
Medicare Australia).
A practice characteristics survey is also collected at
baseline. In addition, participating GPs and PNs complete
a questionnaire that includes demographics, current
Table 1 Outcome measures and collection time points
Measure Baseline 6 months 12 months
Demographic and clinical
measures:
Demographic data, duration of
diabetes
X
Biometric measures: weight, BMI,
waist circumference
X X
HbA1c X X X
Lipids, U&E, spot urine albumin
to creatinine ratio
X X
Medication details, co-morbidities X X
Psychological measures: X X
Health status: AQoL-8D [31] X X
Depressive symptoms: PHQ-9 [32] X X
Diabetes-related distress: PAID [33] X X
Medication taking behaviours:
MARS [34]
X X
Beliefs about insulin: ITAS [35],
additional single items taken
from [36]
X X
Patient experience: excerpts from
GPAQ [37], Consumers Perception
of Informational Continuity [38]
X X
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perceptions and practices regarding insulin initiation,
questions relating to insulin initiation and perceived par-
ticipant willingness from the Diabetes Attitudes, Wishes,
and Needs (DAWN) study [39], relational coordination
[40], collaborative practice scale [41] and questions based
on normalization process theory [42], and the inter-
actional determinants of collaboration [43].
Analysis
Power calculation and sample size
Our sample size calculation is based on the primary out-
come. A total of 224 participants (average of three par-
ticipants per practice) from 74 general practices are
required to detect an absolute 0.5% mean HbA1c differ-
ence over 12 months between control and intervention
groups with 80% power and a standard deviation (SD) of
1 using two-sided alpha of 0.05. Sample size calculation
allows for a design effect of 1.05 and is based on a con-
servative estimate of the intra-cluster correlation (ICC)
for HbA1c of 0.05 [44] and attrition rate of 10% for
practices and participants.
In a community observational study [23], over a five-
year period, about 2% of the community sample changed
from oral treatment to insulin per year. We conserva-
tively assume a background rate 10 times this or 20%
per year in the control group. Based on our pilot study
[29], we estimate 60% will start insulin in the interven-
tion group. A total of 224 participants from 74 general
practices will provide sufficient power to detect a 40%
change in the proportion that transition to insulin
(power = 99.9%, assuming an intra-cluster correlation of
0.3). We will measure and compare the proportion of
participants in each group that reach HbA1c target
although our sample size is not powered to detect a
significant difference in that.
The study will also have at least 80% power to detect
an effect size of 0.5 of 1 SD for psychosocial scores,
assuming an ICC of 0.05.
We do not anticipate a significant confounding of the
results by the attention received by control group partic-
ipants. In control group practices, GPs will be advised to
undertake a clinical review of participating participants.
In these practices, the PN will not receive training or
support. In our intervention the PN once trained plays a
critical enabling role in facilitating a simple in-practice
system for insulin initiation. Without access to a trained
PN and this system, background rates of insulin initi-
ation by GPs in the control arm are likely to approxi-
mate those quoted above.
Statistical analysis
Results will be reported according to CONSORT guide-
lines for cluster randomized trials. A purposely built
survey has been developed. Surveys will be checked for
completeness prior to being scanned and sent for process-
ing with a data management service. Pathology data will
be extracted by the study pathology provider. Data will be
uploaded into Stata 12 for further cleaning and analysis.
Descriptive statistics will be used to summarize GP,
PN, and participant factors for the two study groups and
to check for any imbalance in potential confounders.
The individual participant will be the unit of analysis
and the analytical methods will allow for clustering of
individuals within the practice. Marginal logistic model
using generalized estimating equations with robust stand-
ard errors will be used to compare binary outcomes be-
tween the two study arms. Mixed-effects linear regression
will be used to compare the means between study arms
for continuous outcomes, adjusting for baseline outcome
measure. Stratification variables will be included as fixed
effects. Analysis will be conducted on an intention to treat
basis, with any imbalance of confounders between study
groups adjusted for in the regression analysis.
Economic evaluation
Medicare Benefits Scheme (MBS) and Pharmaceutical
Benefits Scheme (PBS) data between 1 October 2011
and 1 February 2016 will be obtained to examine health
services utilization prior, during, and after study period.
The submission was approved by Medicare Australia in
October 2012 (reference 2012/CO11645). An additional
Medicare consent will be sought from each participant
using the Medicare Australia consent form. Data extrac-
tion will occur in May 2016. Furthermore, a submission
will be made to the Victorian Department of Health to
obtain data linkage on the Victorian Admitted Episodes
Datasets (VAED) and the Victorian Emergency Mini-
mum Datasets (VEMD).
A within-trial Cost-utility analysis (CUA) will be under-
taken from the perspective of the healthcare system. The
primary effectiveness outcome, quality-adjusted life years,
will be calculated from the AQOL-8D. We will calculate
the cost of the Stepping Up Program, distinguishing im-
plementation from establishment and trial-specific costs.
The mean per participant cost of healthcare will be esti-
mated for both intervention and control clients, based on
the audit of clinical records, participant questionnaire and
data linkage, as described above. The intervention group
will incur the additional costs of the Stepping Up Pro-
gram. One-way sensitivity analyses will be undertaken to
identify the key cost and outcome drivers. A stratified
analysis will be used for subgroups where the Stepping Up
Program may have any greater or lesser effectiveness,
defined a priori.
Trial status
Baseline data collection is ongoing and we anticipate will
be completed in February 214. Follow up data collection
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should be completed by mid-2016. Data cleaning or
analysis has not yet begun.
Discussion
The Stepping Up trial has been designed as a transla-
tional study, testing the implementation of a known effi-
cacious intervention (insulin for treating hyperglycemia)
into real world practice in primary care. One of the
study’s key strength is that it is a pragmatic trial examin-
ing the real world effectiveness of reorienting care sys-
tems and the use of existing human healthcare resources
to address a persistent clinical problem. It has important
potential implications for people with T2D, healthcare
professionals, and funders of healthcare though making
better use of scarce healthcare resources, improving timely
access to therapy that can improve disease outcomes.
If successful, it will inform chronic disease and diabetes
routine care, policy, and funding. PNs are the fastest grow-
ing section of the primary care workforce. Almost 60% of
practices employ at least one PN [28], and as core mem-
bers of general practice teams, they are increasingly im-
portant in addressing the epidemic of chronic disease [45],
attracting significant government interest and investment.
PNs potentially have a much broader and more autono-
mous role than traditional clinic nurses, yet overall have
had little formal training in such a role [46]. Prior research
has shown that people with T2D are receptive to en-
hanced PN involvement in their care [47], and that PNs
are keen to enhance their role within diabetes care. PNs
are often able to offer the time, support, and care required
to respond to the psychosocial and emotional needs of
people with T2D [48]. However, local practice context and
culture issues need to be addressed [49]. The Stepping Up
intervention supports the GP/PN team by clarifying roles,
work relationships and responsibilities.
The intervention has the potential to demonstrate
significant improvements in biochemical and clinical
markers known to be associated with improved out-
comes in people with T2D. The study will also provide
important evidence about the impact on psychosocial
outcomes for people with T2D participating in the model
of care and for those commencing insulin therapy in
primary care.
A cost analysis of the Stepping Up program and its
impact on disease progression and downstream costs
within in Australia will have local relevance. This study
will investigate how the costs of diabetes care are af-
fected by better integration of PN, GP, endocrinologist
and CDE-RN in the general practice setting, based on
real-world implementation of the stepping Up program
taking into account the support required to initiate and
sustain change in practice. The expectation is of down-
stream cost savings through reduction of future diabetes-
related complications.
Our proposed study also directly contributes to build-
ing a research culture in Australian general practice. The
practices (GPs and PNs) involved in Stepping Up will be
supporting part of a state wide practice-based research
network to enhance primary care research capacity in
Australia.
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